Juno Therapeutics, Inc. (JUNO) insider have most recently took part in a trading activity. On Jun 20, 2017 Evnin Anthony B, Director bought 9,000 shares having total worth of $219,600 at the price of $24.4 per share, following the transaction a total of 66,301 shares owned by Evnin Anthony B. Before this latest buy, Evnin Anthony B purchased JUNO at 1 other times during the past twelve months, for a total investment of $176,880 at an average of $22.11 per share.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 10 times by insiders. In 8 of these trades, the insider was a seller while an employee of the company was the buyer in 2 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Juno Therapeutics, Inc. (JUNO) traded up 7.18% on Jun 21, 2017, hitting $26.43. 3,538,890 shares of the company’s stock traded hands. Juno Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $48.5. The company’s market cap is $0 million.
Juno Therapeutics, Inc. (JUNO) last announced its earnings results on May 4, 2017. The company reported -0.71 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.71. The company had revenue of $19 million for the quarter, compared to the consensus estimate of $13 million. During the same quarter in the previous year, the company posted -0.78 earnings per share. The company’s revenue for the quarter was up 98% on a year-over-year basis.
|earnings per share||-0.71||-0.65||-0.57||-0.64||-0.78||-0.53|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018